Finally know enough about how the brain breaks to focus on fixing it, experts say

Researchers at the Allen Institute for Brain Science in Seattle have launched the Brain Health accelerator, a $400 million initiative designed to accelerate therapies for brain disorders. The program aims to develop new genetic therapies, including gene editing and traditional gene therapy, for diseases such as Alzheimer's, Parkinson's, ALS, Lewy body dementia, and Huntington. Ed Lein notes that advances in gene control enable precise, targeted treatments, while John Ngai highlights rapid progress since the BRAIN Initiative was unveiled in 2013. Funders include $200 million from the Allen Institute, $100 million from the Bezos family, and $100 million from NIH, Amazon Web Services, and EverythingALS, with collaborators spanning hospitals, universities, and research centers worldwide. The accelerator seeks to translate brain research into clinical applications through collaborative data sharing to enhance translational research and predictive models. The program draws on experiences like Jeff Carroll’s Huntington’s work, illustrating personal motivation behind translational neuroscience, and aims to scale research beyond small labs by leveraging shared infrastructure to inform drug discovery and clinical development.